SCHEMBL1889253

SCHEMBL1889253

Cc1noc(C)c1-c1nc2c(C)cccc2cc1CBr

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 8/20 0.39
BRD2 P25440 5/20 0.39
CREBBP Q92793 3/20 0.39
NPC1 O15118 1/20 0.38
POLB P06746 1/20 0.38
CASP3 P42574 1/20 0.38
RAB9A P51151 1/20 0.38
SENP7 Q9BQF6 1/20 0.38
ATM Q13315 1/20 0.37
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
RXFP1 Q9HBX9 2/20 0.36
DRD4 P21917 1/20 0.36
DRD3 P35462 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
PIK3CD O00329 3/20 0.35
MAPT P10636 2/20 0.35
BRD3 Q15059 1/20 0.35
CTSA P10619 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1881980 0.87 MEN1 (0.48) BRD4BRD2CREBBPNPC1POLB
SCHEMBL1885747 0.79 ATM (0.40) ATMMEN1KMT2ARXFP1DRD4
SCHEMBL1884046 0.77 ERN1 (0.49) BRD4BRD2CREBBPNPC1POLB
SCHEMBL1878147 0.76 PIK3CD (0.39) BRD4BRD2CREBBPPOLBPIK3CD
SCHEMBL1883185 0.76 ACACB (0.44) BRD4RXFP1PIK3CDCTSA
SCHEMBL1884319 0.75 PIK3CD (0.47) ATMDRD4DRD3L3MBTL1PIK3CD
SCHEMBL1598219 0.75 ATM (0.52) ATMDRD4DRD3L3MBTL1PIK3CD
SCHEMBL1879468 0.74 PIK3CD (0.42) ATMMEN1KMT2ADRD4DRD3
SCHEMBL1884684 0.73 BRD4 (0.36) BRD4BRD2CREBBPNPC1POLB
SCHEMBL1877014 0.73 PIK3CD (0.54) RAB9AATMDRD4DRD3L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8399483-B2 Quinoxaline and quinoline derivatives as kinase inhibitors UCB PHARMA S.A. (BE) 2013-03-19 US disclosed
US-20110105508-A1 QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA, S.A. (BE) 2011-05-05 US disclosed
EP-2231641-A2 QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS UCB Pharma, S.A. (BE) 2010-09-29 EP disclosed
WO-2009081105-A2 QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-07-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105508-A1 QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS PDXK, PDPK1, PIKFYVE BRD4 487/4885BRD2 965/4885CREBBP 2115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.